Dollars for Profs
Dig Into University Researchers' Outside Income and Conflicts of Interest
Published Dec. 6, 2019
This database was last updated in December 2019 and should only be used as a historical snapshot. There may be new or amended records not reflected here.
Conflict of Interest
Institutions must file significant disclosures to the National Institutes of Health if they determine financial relationships could affect the design, conduct or reporting of the NIH-funded research. The NIH provided us with their entire financial conflict of interest database, with filings from 2012 through 2019.
Should you be removed from our database? Contact us at [email protected]. Read more below.
Lia Gore
Children's Hosp of Philadelphia, Department: Na
Should you be removed from our database? Contact us at [email protected]. Read more below.
Novartis, Inc.
Other : Advisory Board Member
Dr. Lia Gore has a significant financial interest due to her role as an advisory board member with Novartis, Inc. Dr. Lia Gore is a co-investigator on “ADVL1521: A Phase 2 study of the MEK inhibitor Trametinib (IND# 119346, NSC# 763093) in Children with Relapsed or Refractory Juvenile Myelomonocytic Leukemia” (protocol). Novartis, Inc. is the manufacturer of the protocol study drug, Trametinib. This protocol is funded under project UM1CA097452.
Pediatric Phase 1/Pilot Consortium
The Children's Oncology Group Phase 1 and Pilot Consortium comprises 21 premier pediatric oncology centers in North America. Our primary goal is to efficiently develop new anti-cancer agents and therapeutic strategies for children with recurrent or refractory cancer to increase the overall cure rate for childhood cancer. We also strive to develop targeted anti-cancer therapies that reduce long term side effects.
Filed on August 01, 2018.
Tell us what you know about Lia Gore's disclosure
We're still reporting about conflicts of interest. Is there something you'd like to tell us about this disclosure?
Other search results for: “Lia Gore”
| Name | Institution | Type | Company | Disclosed Value |
|---|---|---|---|---|
| Lia Gore | Children's Hosp of Philadelphia | Conflict of Interest | Novartis, Inc | $5,000 - $9,999 |
Notes: When a more specific filing date is not available for an individual financial disclosure or conflict of interest form, we use the year the form was filed. If the year was not disclosed, we report the range of years covered by our public records requests. In a few cases, a start date was provided instead of a filing date. In those cases, we use the start date instead.
Fewer than 10% of records from the University of Florida and fewer than 1% of records from the University of Texas system were removed because they did not contain enough information.
ProPublica obtained additional financial disclosures and conflict of interest forms that we have not yet digitized and added to the database. You can download those disclosures in the ProPublica Data Store.